Journal
JOURNAL OF THORACIC ONCOLOGY
Volume 3, Issue 1, Pages 84-93Publisher
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0b013e31815efe24
Keywords
non-small cell lung cancer; adjuvant chemotherapy; molecular markers; biomarkers; KRAS (Kirsten rat sarcoma viral oncogene homolog); EGFR (epidermal growth factor receptor); ERCC1 (excision repair cross-complementation group 1); p27(Kip1); MRP2 (multidrug resistance protein 2); bTubIII (class III beta-tubulin)
Categories
Ask authors/readers for more resources
In patients with previously-untreated, completely-resected pathologic stage II-III non-small cell lung cancer, 4 months of postoperative cisplatin-based chemotherapy reduces the risk of death by approximately 20%. To date, the only prospectively validated prognostic and predictive factor which can be used to guide clinical practice is pathologic stage. Higher stage patients have a worse prognosis, but derive more benefit from adjuvant chemotherapy. Numerous molecular markers are being developed with the potential to help decide which patients to treat with adjuvant chemotherapy, and which drugs to use. This paper will review the molecular markers which are having immediate impact on treatment decisions in routine practice, and which merit further study in the next generation of adjuvant chemotherapy trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available